|Bid||24.20 x 2200|
|Ask||24.30 x 800|
|Day's Range||23.45 - 24.37|
|52 Week Range||10.85 - 25.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.09|
The U.S. has had monthslong shortages of Mylan’s EpiPen and other products, causing parents to worry as back-to-school season approaches.
Here are a few things to know about the EpiPen shortage. The U.S. Food and Drug Administration has confirmed that there is in fact a shortage of EpiPens. The shortage has actually been going on for months, but is only kick up more dust lately as school starts.
Teva received FDA approval of a generic version of Mylan's EpiPen, but it didn't make the device. Here's who did.
Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.
Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.
Mylan reported its second-quarter results on August 8. Mylan had completed a $1.0 billion share repurchase program at the beginning of 2018, the benefits of which are reflected in its adjusted EPS growth. In the second quarter, Mylan’s gross profit fell ~40% YoY to $962.5 million.
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Shares of Teva jumped on Thursday after gaining FDA approval for its generic version of the EpiPen and announcing positive data results on its Fasinumab drug ...
Whistleblower protections at Royal Bank of Canada are under scrutiny. The UK’s Financial Conduct Authority is investigating after a former trader at Canada’s biggest bank won his case for unfair dismissal and at least five more potentially similar cases came to light. The London-based RBC staff involved claim to have been dismissed without due process after highlighting legal and compliance problems across a range of businesses in cases spanning several years, multiple people familiar with the matter told the Financial Times.
Friday, August 17: Google employees sign protest letter over Google working on a censored version of Google in China; Teva gets FDA approval for generic EpiPen right after Buffett doubled his stake; Yahoo Finance survey results on sentiment about Trump and NFL protests. Yahoo Finance’s Dan Roberts delivers the news before your weekend.